Literature DB >> 15630716

It's good to feel better but it's better to feel good.

Maxime Dougados.   

Abstract

Mesh：

Year:  2005        PMID： 15630716

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  12 in total

1.  Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change.

Authors:  Jos Hendrikx; Jaap Fransen; Wietske Kievit; Piet L C M van Riel
Journal:  Qual Life Res       Date:  2014-09-25       Impact factor: 4.147

Review 2.  [Treat-to-target from the patient perspective].

Authors:  E Gromnica-Ihle; M Rink
Journal:  Z Rheumatol       Date:  2011-10       Impact factor: 1.372

3.  Identification of cut-points in commonly used hip osteoarthritis-related outcome measures that define the patient acceptable symptom state (PASS).

Authors:  Alicia J Emerson Kavchak; Chad Cook; Eric J Hegedus; Alexis A Wright
Journal:  Rheumatol Int       Date:  2013-06-29       Impact factor: 2.631

Review 4.  Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis.

Authors:  Silvia Rosina; Giulia Camilla Varnier; Marta Mazzoni; Stefano Lanni; Clara Malattia; Angelo Ravelli
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

Review 5.  Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?

Authors:  Tore K Kvien; Turid Heiberg; Kåre B Hagen
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 6.  Applying science in practice: the optimization of biological therapy in rheumatoid arthritis.

Authors:  Sofia Ramiro; Pedro Machado; Jasvinder A Singh; Robert B Landewé; José António P da Silva
Journal:  Arthritis Res Ther       Date:  2010-11-04       Impact factor: 5.156

7.  Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.

Authors:  Maxime Dougados; Alan Moore; Shaohua Yu; Xavier Gitton
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

8.  Short-term efficacy of rofecoxib and diclofenac in acute shoulder pain: a placebo-controlled randomized trial.

Authors:  Maxime Dougados; Anne Le Henanff; Isabelle Logeart; Philippe Ravaud
Journal:  PLoS Clin Trials       Date:  2007-03-09

9.  Patient acceptable symptom states after totalhip or knee replacement at mid-term follow-up: Thresholds of the Oxford hip and knee scores.

Authors:  J C Keurentjes; F R Van Tol; M Fiocco; C So-Osman; R Onstenk; A W M M Koopman-Van Gemert; R G Pöll; R G H H Nelissen
Journal:  Bone Joint Res       Date:  2014-01-13       Impact factor: 5.853

Review 10.  Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk.

Authors:  Robert Andrew Moore; Sheena Derry; Lee S Simon; Paul Emery
Journal:  Pain Pract       Date:  2013-08-14       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.